Skip to main content

Ultragenyx Pharmaceutical Inc.

RARE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001515673

In the last 90 days, Ultragenyx Pharmaceutical Inc. insiders filed 0 open-market purchases and 5 sales; 311 institutions reported holding it in 13F filings for Q2 2026, worth $3.55B in total; no superinvestor holds it.

Superinvestors holding RARE, Q2 2026

See all superinvestors

No superinvestor reported holding RARE in Q2 2026.

Moves by quarter

Superinvestors that opened, added to, trimmed or sold out of RARE each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.

  1. Q2 2025

    0 superinvestors holding at quarter end

    Sold out
    Duquesne Family Office
  2. Q3 2024

    1 superinvestor holding at quarter end

    New
    Duquesne Family Office
  3. Q4 2021

    0 superinvestors holding at quarter end

    Sold out
    Maverick Capital
  4. Q3 2021

    1 superinvestor holding at quarter end

    Reduced
    Maverick Capital (−42.4%)
  5. Q2 2021

    1 superinvestor holding at quarter end

    Reduced
    Maverick Capital (−9.0%)